OCUL: FDA-aligned NDA submission for a superior wet AMD therapy targeted for Q4 2024, with rapid adoption expected
The session highlighted strong FDA alignment for a single pivotal trial submission, with NDA filing targeted for Q4 2024 and a planned 2027 launch. SOL-1 data showed statistically significant superiority over EYLEA, and the company is well-positioned for rapid commercial adoption and expansion into…